“…16e19 While pharmacokinetic data demonstrated a low and variable oral bioavailability suggesting the requirement for a 6-h dosing interval, the pharmacodynamic data suggested a 12e24-h dosing interval is adequate to ensure betablockade. 16,17,19,20 Uechi et al reported the cardiovascular and renal effects of oral carvedilol (0.2e0.8 mg/kg q 24 h) in dogs with experimental MR and control dogs suggesting that a dose of 0.4 mg/kg PO q 24 h may be a reasonable target dose in dogs with heart disease. 20 Carvedilol is currently used by some veterinarians in preclinical CVD and other cardiac diseases, however dosing is variable.…”